BILLING CODE	Must use valid NDC
BENEFIT TYPE	Pharmacy
STATUS	Prior Authorization Required

Firdapse was approved in 2018 for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. As of 2022, it is also indicated for pediatric patients who are at least 6 years of age, although LEMS is extremely uncommon in pediatrics. LEMS is a rare autoimmune disorder of the neuromuscular junction. Autoantibodies damage the motor nerve membrane leading to reduced release of acetylcholine. This results



If all the above requirements are met, the medication will be approved for 3 months.

For reauthorization:

1. Chart notes must document improved muscle strength.

If all the above requirements are met, the medication will be approved for an additional 12 months.

CareSource considers Firdapse (amifampridine) not medically necessary for the treatment of conditions that are not listed in this document. For any other indication, please refer to the Off-